Shawn Alter, PhD

Improvement in Anxiety Symptoms in Depressed Patients Treated with AXS-05 (Dextromethorphan-Bupropion): Results from the EVOLVE Open-label, Long-term Study

Abstract: Background: Innovative therapies to treat individuals with MDD, especially those with comorbid anxiety, are urgently needed. AXS-05 (dextromethorphan HBr 45 mg- bupropion HCl...

Shawn Alter , PhD;

Zachariah Thomas , DPM, AACFAS;

01/19/2023

Improvements in Cognitive and Physical Functioning Outcomes in Depressed Patients Treated with AXS-05 (Dextromethorphan-Bupropion): Results from the EVOLVE Open-Label, Long-Term Study

AXS-05 exhibited rapid and sustained improvements in cognitive and physical functioning in individuals with MDD who previously tried one or more prior antidepressants. This study also sho...

Shawn Alter , PhD;

10/26/2023

Studying the Impact of Patient Treatment Experiences on Patient Hope for Major Depressive Disorder Pharmacotherapies

Abstract: Background: Individuals receiving treatment for major depressive disorder (MDD) continue to face multiple disease or treatment-related issues. A web-based survey was conducted w...

Shawn Alter , PhD;

Iresha Abeynayake ;

01/19/2023